Subsequently, two subgroup analyses pooling studies according to the chemotherapy regimens administered to the breast cancer patients revealed that HER2+ patients treated with TP regimen [94, 97, 115] were significantly associated with better response (OR 4.64; 95% CI 2.74–7.86; p<0.00001), while HER2 was not associated with treatment response in patients treated with anthracycline-containing regimen (84,141) (OR 2.08; 95% CI 0.90–4.78; p=0.09). Here, ERBB2 is linked to breast carcinoma.